Fa-Chyi Lee is an Oncology physician affiliated with University of California, Irvine. OpenAlex indexes 69 publications with 2,584 citations (h-index 12); ClinicalTrials.gov lists 6 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
101 The City Dr S Bldg 23
Orange, CA 928683201
Telephone
714-456-8000Provider last certified this registry record 7 Mar 2023.
Clinical trials
6 registered studies on ClinicalTrials.gov matched to this name. Itemized trial rows, roles and sponsors are part of the full profile. Why? →
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Astellas Pharma US IncProgram year20241 payment
- Foundation Medicine, Inc.Program year20231 payment
- JAZZ PHARMACEUTICALS INC.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
28.9%Kinase inhibitor22.4%Imatinib Mesylate55%Lenvima46%Part D<11 patientsNucleoside Analog Antiviral6.5%Lonsurf100%Part D<11 patientsNervous system
26.5%Phenothiazine7.8%Prochlorperazine Maleate100%Part D≥19 patientsGabapentinoids6.1%Gabapentin100%Part D<11 patients+ 3 more classes in this area
Metabolism & gastrointestinal
24.1%Serotonin-3 Receptor Antagonist12.9%Ondansetron Hcl61%Ondansetron Odt40%Part D<11 patientsAntidiarrheal microorganisms7.5%Creon100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Evaluation of the NorthStar ctDNA assay for monitoring gastrointestinal malignancies: A retrospective analysis.
Journal of Clinical Oncology
2026 - 492 Phase 2 single-arm study of trans-arterial tirapazamine embolization (TATE) plus pembrolizumab for liver metastatic colorectal cancer who have progressed on at least two lines of chemotherapy
Regular and Young Investigator Award Abstracts
2025 - Hereditary Cancer Clinics Improve Adherence to NCCN Germline Testing Guidelines for Pancreatic Cancer
Journal of the National Comprehensive Cancer Network
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Susan O’Brien, MD
University of California, Irvine
Steven Potkin, MD
University of California, Irvine
Stefan Ciurea, MD
University of California, Irvine
Farshid Dayyani, MD
University of California, Irvine
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”